Who are the top shareholders of the Bayer CropSci.?

The top shareholders of Bayer CropScience include Bayer Vapi Private Limited with 17.89%, mutual funds holding 8.69%, foreign institutional investors at 3.49%, and individual investors collectively owning 8.88%. The largest public shareholder is Quant Mutual Fund, specifically the Quant Small Cap Fund, with a 2.32% stake.

The top shareholders of Bayer CropScience include Bayer Vapi Private Limited, which holds the highest stake at 17.89%. Additionally, the company has a diverse range of shareholders, with mutual funds holding 8.69% across 25 schemes and foreign institutional investors (FIIs) holding 3.49% through 143 different entities. The highest public shareholder is Quant Mutual Fund, specifically the Quant Small Cap Fund, with a holding of 2.32%. Individual investors collectively own 8.88% of the company.

What does Bayer CropSci. do?

Bayer CropScience Ltd, established in 1958, is a leading Indian company in the agriculture sector, focusing on pesticides and agrochemicals, with a market cap of Rs 24,831 Cr and a net profit of 143 Cr as of March 2025. Key metrics include a P/E ratio of 44.00 and a dividend yield of 2.25%.

Overview:<BR>Bayer CropScience Ltd is a key player in the Indian agriculture industry, specializing in pesticides and agrochemicals, and is categorized as a Large Cap company.<BR><BR>History:<BR>Bayer CropScience Ltd was incorporated in 1958 and was formerly known as Bayer (India) Limited until its name change on February 24, 2004. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,046 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 143 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 24,831 Cr (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 44.00<BR>- Industry P/E: 38<BR>- Dividend Yield: 2.25%<BR>- Debt Equity: -0.43<BR>- Return on Equity: 19.93%<BR>- Price to Book: 8.77<BR><BR>Contact Details:<BR>- Address: Bayer House Central Avenue, Hiranandani Estate Thane (West) Maharashtra : 400607<BR>- Tel: 91-022-25311234<BR>- Email: ir_bcsl@bayer.com<BR>- Website: http://www.bayer.in

When is the next results date for Bayer CropSci.?

No Upcoming Board Meetings

Has Bayer CropSci. declared dividend?

Yes, Bayer CropScience Ltd has declared a 900% dividend, amounting to ₹90 per share, with an ex-date of November 28, 2024. While recent performance shows a -8.52% return over the last 6 months, longer-term returns have been positive, particularly with a total return of 31.9% over the past 2 years.

Bayer CropScience Ltd has declared a 900% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 900%<BR>- Amount per share: 90 per share<BR>- Ex-date: 28 Nov 2024<BR><BR>Dividend Yield: 2.25%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -8.52%, the dividend return was 0%, resulting in a total return of -8.52%.<BR><BR>Over the past year, the price return was 0.48%, the dividend return was 2.06%, leading to a total return of 2.54%.<BR><BR>In the 2-year period, the price return was 25.8%, the dividend return was 6.10%, which culminated in a total return of 31.9%.<BR><BR>For the 3-year period, the price return was 4.25%, the dividend return was 7.91%, resulting in a total return of 12.16%.<BR><BR>In the last 4 years, the price return was 4.34%, the dividend return was 9.47%, leading to a total return of 13.81%.<BR><BR>Over the past 5 years, the price return was 2.76%, the dividend return was 9.05%, culminating in a total return of 11.81%.<BR><BR>Overall, Bayer CropScience Ltd has declared a significant dividend, and while the recent 6-month performance shows a decline, the longer-term returns indicate a positive trend, particularly in the 2-year and 3-year periods.

Who are the peers of the Bayer CropSci.?

Bayer CropSci.'s peers include P I Industries, UPL, Sumitomo Chemical, Dhanuka Agritech, Sharda Cropchem, Rallis India, Bhagiradha Chemical, Bharat Rasayan, and NACL Industries. Management risk varies from excellent to average among peers, with Sharda Cropchem showing the highest 1-year return at 102.43%, while Bayer CropSci. has a 1-year return of 10.06%.

Peers: The peers of Bayer CropSci. are P I Industries, UPL, Sumitomo Chemi., Dhanuka Agritech, Sharda Cropchem, Rallis India, Bhagiradha Chem., Bharat Rasayan, and NACL Industries.<BR><BR>Quality Snapshot: Excellent management risk is observed at Bayer CropSci., Dhanuka Agritech, and P I Industries, while Good management risk is found at Sumitomo Chemi., Sharda Cropchem, and Bharat Rasayan, and Average management risk is present at UPL, Rallis India, Bhagiradha Chem., and NACL Industries. Growth is rated as Excellent for P I Industries, while Below Average growth is seen at Bayer CropSci., UPL, Sumitomo Chemi., Dhanuka Agritech, Sharda Cropchem, Rallis India, Bhagiradha Chem., Bharat Rasayan, and NACL Industries. Capital Structure is rated Excellent for Bayer CropSci., P I Industries, Sumitomo Chemi., Dhanuka Agritech, Sharda Cropchem, and Bharat Rasayan, while Good capital structure is found at Bhagiradha Chem., and Average capital structure is present at UPL, Rallis India, and NACL Industries.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Sharda Cropchem at 102.43%, while the lowest is Bharat Rasayan at -12.17%. Bayer CropSci.'s 1-year return is 10.06%, which is higher than Bharat Rasayan's but lower than Sharda Cropchem's. Additionally, the six-month return is negative for Bayer CropSci., UPL, Sumitomo Chemi., and Bharat Rasayan.

Who are in the management team of Bayer CropSci.?

As of March 2022, Bayer CropSci's management team includes Pankaj Patel (Chairman), Duraiswami Narain (CEO), and Simon Britsch (CFO), along with several independent and non-executive directors. The team is diverse, covering various roles in leadership and compliance.

As of March 2022, the management team of Bayer CropSci includes the following members:<BR><BR>1. Pankaj Patel - Chairman & Independent Director<BR>2. Duraiswami Narain - Vice Chairman, Managing Director & CEO<BR>3. Ketaki Bhagwati - Non-Executive & Independent Director<BR>4. Thomas Hoffmann - Non-Executive & Non-Independent Director<BR>5. Sekhar Natarajan - Non-Executive & Independent Director<BR>6. Nikunjkumar Savaliya - Company Secretary & Compliance Officer<BR>7. Harsh Kumar Bhanwala - Non-Executive & Independent Director<BR>8. Simon Wiebusch - Whole-time Director<BR>9. Simon Britsch - Executive Director & CFO<BR>10. Brian Naber - Non-Executive & Non-Independent Director<BR><BR>This diverse team encompasses various roles, including independent directors, executive positions, and compliance oversight.

How big is Bayer CropSci.?

As of 24th July, Bayer CropScience Ltd has a market capitalization of 28,727.00 Cr, with recent net sales of 5,472.60 Cr and a net profit of 568.00 Cr.

As of 24th July, Bayer CropScience Ltd has a market capitalization of 28,727.00 Cr, categorizing it as a Large Cap company.<BR><BR>For the latest four quarters, Bayer CropScience reported Net Sales of 5,472.60 Cr and a Net Profit of 568.00 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 2,849.40 Cr and Total Assets of 4,597.10 Cr.

Is Bayer CropSci. technically bullish or bearish?

As of October 16, 2025, Bayer CropSci. exhibits a bearish trend with significant weakness, indicated by bearish MACD, moving averages, and KST across multiple time frames, despite a mildly bullish signal from Dow Theory.

As of 16 October 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Bayer CropSci. is bearish with a strong indication of weakness. The weekly MACD is bearish, and the daily moving averages confirm this bearish outlook. The KST is also bearish on both weekly and monthly time frames. While the Bollinger Bands are mildly bearish, the Dow Theory shows a mildly bullish signal on the weekly chart, which is not strong enough to counter the overall bearish sentiment. The stock has underperformed significantly over the past year, with a return of -24.30% compared to the Sensex's 2.41%. Overall, the indicators suggest a bearish trend with considerable weakness.

Is Bayer CropSci. overvalued or undervalued?

As of October 17, 2025, Bayer CropScience is considered overvalued with a PE ratio of 38.24 and a year-to-date return of -9.24%, indicating it may not be a favorable investment compared to its peers and the Sensex.

As of 17 October 2025, Bayer CropScience's valuation grade has moved from very expensive to expensive, indicating a slight improvement but still reflecting a high valuation. The company is currently considered overvalued. Key ratios include a PE ratio of 38.24, an EV to EBITDA of 30.04, and a Price to Book Value of 7.95, all of which suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Bayer CropScience's PE ratio is higher than UPL's 37.91 and BASF India's 47.93, which are both classified as attractive. The PEG ratio stands at 0.00, indicating no growth expectations factored into the price, which is concerning. Recent stock performance shows that Bayer has underperformed against the Sensex, with a year-to-date return of -9.24% compared to the Sensex's 7.44%, reinforcing the notion that the stock may not be a favorable investment at its current valuation.

Are Bayer CropSci. latest results good or bad?

Bayer CropScience's Q2 FY26 results show strong revenue and profit growth, with net profit up 94.50% quarter-on-quarter. However, declining operating margins and a negative five-year EBIT growth rate suggest underlying challenges, making the overall performance mixed.

Bayer CropScience's latest results for Q2 FY26 show a mixed performance. On one hand, the company reported a significant increase in net profit to ₹278.70 crores, which is a 94.50% increase quarter-on-quarter and a 9.64% increase year-on-year. Additionally, revenue surged to ₹1,914.60 crores, reflecting an impressive 82.97% growth from the previous quarter and a 17.36% increase compared to the same quarter last year. <BR><BR>However, there are concerning signs as well. The operating margin has declined by 106 basis points year-on-year to 18.20%, despite the strong revenue growth, indicating potential challenges in maintaining profitability. Furthermore, the five-year EBIT growth rate is negative at -3.98%, suggesting structural issues that could impact future performance.<BR><BR>Overall, while the quarterly results show strong revenue and profit growth, the declining margins and long-term profitability concerns indicate that the results are not entirely positive. Investors should be cautious and consider the underlying challenges facing the company.

Should I buy, sell or hold Bayer CropSci.?

How has been the historical performance of Bayer CropSci.?

Bayer CropSci. has shown increasing net sales, reaching 5,473.40 Cr in March 2025, but experienced declines in operating profit, profit before tax, and profit after tax. Despite asset growth to 5,236.20 Cr, cash flow from operating activities significantly decreased, resulting in a net cash outflow of 271.00 Cr.

Answer:<BR>The historical performance of Bayer CropSci. shows a trend of increasing net sales and operating income over the years, with net sales reaching 5,473.40 Cr in March 2025, up from 5,106.20 Cr in March 2024 and 5,139.70 Cr in March 2023. However, operating profit (PBDIT) has seen a decline from 1,035.00 Cr in March 2024 to 809.30 Cr in March 2025. Profit before tax also decreased to 707.40 Cr in March 2025 from 941.40 Cr in March 2024, while profit after tax fell to 568.00 Cr from 740.50 Cr in the same period. The company's total assets increased to 5,236.20 Cr in March 2025, compared to 4,597.10 Cr in March 2024, indicating growth in the asset base. Total liabilities also rose to 5,236.20 Cr from 4,597.10 Cr, reflecting an increase in financial obligations. Cash flow from operating activities decreased significantly to 262.00 Cr in March 2025 from 951.00 Cr in March 2024, contributing to a net cash outflow of 271.00 Cr in March 2025.<BR><BR>Breakdown:<BR>Bayer CropSci. has demonstrated a consistent increase in net sales, achieving 5,473.40 Cr in March 2025, a rise from previous years, although operating profit has declined from 1,035.00 Cr in March 2024 to 809.30 Cr in March 2025. Profit before tax and profit after tax also saw reductions, with figures of 707.40 Cr and 568.00 Cr respectively in March 2025. The total assets of the company increased to 5,236.20 Cr, indicating a growing asset base, while total liabilities rose correspondingly to the same figure, suggesting a balance between asset growth and financial obligations. The cash flow from operating activities has notably decreased to 262.00 Cr, leading to a net cash outflow of 271.00 Cr, which highlights challenges in cash generation despite the growth in sales.

Which are the latest news on Bayer CropSci.?

Why is Bayer CropSci. falling/rising?

As of 03-Dec, Bayer CropScience Ltd's stock is declining, currently priced at 4,511.90, with a year-to-date drop of -18.76% and significant underperformance compared to market benchmarks. The stock is trading below key moving averages, indicating a consistent downward trend and diminished investor interest.

As of 03-Dec, Bayer CropScience Ltd's stock price is falling, currently at 4,511.90, reflecting a change of -91.2 (-1.98%). The stock has underperformed the sector today by -1.61% and reached an intraday low of Rs 4,499.9, which is a decline of -2.24%. Over the past week, the stock has decreased by -1.48%, while the benchmark Sensex has only fallen by -0.59%. <BR><BR>In terms of longer-term performance, Bayer CropScience has shown significant declines, with a year-to-date drop of -18.76% compared to the Sensex's gain of +8.92%. Over the past year, the stock has decreased by -27.20%, while the broader market has increased by +5.27%. The stock's performance over three years is also concerning, with a decline of -2.59% against a benchmark increase of +35.37%.<BR><BR>Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a consistent downward trend. Investor participation has also diminished, with delivery volume falling by -75.17% compared to the 5-day average. <BR><BR>The company's financial health presents further challenges, as it has experienced a poor long-term growth rate in operating profit of -3.22% over the last five years. Recent financial results have shown flat performance, with net sales declining by -10.60%. The stock is perceived as expensive with a Price to Book Value of 6.5, despite a relatively high return on equity (ROE) of 19.5%. <BR><BR>Overall, the combination of poor performance metrics, declining investor interest, and unfavorable comparisons to market benchmarks contribute to the stock's falling price.